Professor Weijun Fan, head advisor of the Department of Minimally Invasive Interventional Therapy at Sun Yat-sen University Cancer Center, serves as Chief Physician and Doctoral Supervisor in the department. He currently hold the position of Chairman of the Tumor Ablation Treatment Committee under the CHINA ANTI CANCER ASSOCIATION (CACA); Chairman of the Second Term Committee on Tumor Ablation Therapy within the Chinese Society of Clinical Oncology (CSCO); Designate Chair of CSCO’s Radiological Intervention Therapy Committee; Vice Chairman of the Interventional Medicine Professional Committee of the Chinese Association of Integrative Medicine; Leader of the Tumor Ablation Technology Expert Group under the Chinese Medical Doctor Association (CMDA); Head of the Ablation Technology Expert Group at the National Health Commission’s Competency Building & Continuing Education Center; Chairman of the Guangdong Anticancer Association’s Minimally Invasive Oncology Committee; and Chief Scientist of the National Key Research and Development Program project.  

Dedicated to foundational and clinical research on solid tumor ablation for decades, Professor Fan is a leading authority and a pioneering figure in China's tumor ablation field, having established standardized training protocols for the discipline. He established the landmark ‘Three-Stage’ CMDA Tumor Ablation Training System, organized 86 specialized national training programs across China that have certified over 16,000 practitioners. As editor-in-chief, he compiled China’s first suite of standardized CMDA training textbooks—Liver Tumor Ablation Therapy, Lung Tumor Ablation Therapy, Thyroid Tumor Ablation Therapy, and Selected Cases in Microwave Ablation for Lung Tumors. And he is the editor of the first monograph—Microwave Ablation Therapy for Tumors on tumor microwave ablation in China and abroad. With over 50 peer-reviewed publications in prestigious journals, he leads multiple grants including one National Key R&D Program, three National Natural Science Foundation projects, and several provincial key initiatives. In recognition of his contributions, Professor Fan was honored with the Third ‘National Renowned Physician • Outstanding Style’ Award in 2019.  

More than fifty papers were published in core Journals in China, and more than twenty SCI papers were published on high influential SCI scientific journals, such as Journal of experimental & clinical cancer research, BMC medcine, International journal of surgery, Cancer, Advanced Materials, Hepatology, Liver international, Cancer Immunology Immunotherapy, Int Immunopharmacol, International Journal of Hyperthermia, AJR, and JVIR.

1.Tan H, Jiang Y, Shen L, Nuerhashi G, Wen C, Gu L, Wang Y, Qi H, Cao F, Huang T, Liu Y, Xie W, Deng W, Fan W. Cryoablation-induced neutrophil Ca2+ elevation and NET formation exacerbate immune escape in colorectal cancer liver metastasis. J Exp Clin Cancer Res. 2024 Dec 9;43(1):319. doi: 10.1186/s13046-024-03244-z. PMID: 39648199; PMCID: PMC11626751.
2.Shen L, Cao F, Liu Y, Nuerhashi G, Lin L, Tan H, Wen C, Wang Y, Chen S, Zou H, Xie L, Fan W. Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial. BMC Med. 2025 May 9;23(1):275. doi: 10.1186/s12916-025-04110-1. PMID: 40346494; PMCID: PMC12065160.
3.Chen S, Shen L, Fan W. Letter to the Editor: The divergences in the efficacy of adjuvant transarterial chemoembolization for HCC- In-depth analysis and enlightenments. Hepatology. 2025 Mar 18. doi: 10.1097/HEP.0000000000001310. Epub ahead of print. PMID: 40100369.
4.Chen S, Shen L, Lin L, Qi H, Chang B, Zeng Q, Lu L, Huang J, Tan H, Cao F, Xie L, Huang T, Wu Y, Wen C, Wang Y, Tang R, Li C, Zheng G, Nuerhashi G, Fan W. Development and validation of the NTAA prognostic model for BCLC stage B hepatocellular carcinoma undergoing transarterial chemoembolization: a retrospective multicenter cohort study. Int J Surg. 2025 Aug 7. doi: 10.1097/JS9.0000000000003138. Epub ahead of print. PMID: 40773250.
5.Zuo M, Zheng G, Cao Y, Lu H, Li D, An C, Fan W. Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high risk: a propensity score matching study. Int J Surg. 2025 Jan 1;111(1):104-112. doi: 10.1097/JS9.0000000000001940. PMID: 38995173; PMCID: PMC11745606.
6.Li X, Fan W, Zhang L, Zhao M, Huang Z, Li W, Gu Y, Gao F, Huang J, Li C, Zhang F, Wu P. CT-guided percutaneous microwave ablation of adrenal malignant carcinoma: preliminary results. Cancer. 2011 Nov 15;117(22):5182-8. doi: 10.1002/cncr.26128. Epub 2011 Apr 26. PMID: 21523760.
7.Shen L, Jiang Y, Wu Y, Li C, Zeng Q, Lin L, Wang Y, Chen S, Cao F, Nuerhashi G, Zhang S, Zhou Z, An C, Du Z, Fan W. The Value of no Evidence of Disease (NED) in Intermediate-Stage Hepatocellular Carcinoma After TACE: A Real-World Study. Liver Int. 2025 May;45(5):e70101. doi: 10.1111/liv.70101. PMID: 40231897.
8.Chen S, Shen B, Wu Y, Shen L, Qi H, Cao F, Huang T, Tan H, Wen C, Fan W. The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy. Int Immunopharmacol. 2023 Jun;119:110228. doi: 10.1016/j.intimp.2023.110228. Epub 2023 Apr 28. PMID: 37121111.
9.Liu D, Cao F, Xu Z, Zhao C, Liu Z, Pang J, Liu ZX, Moghiseh M, Butler A, Liang S, Fan W, Yang J. Selective Organ-Targeting Hafnium Oxide Nanoparticles with Multienzyme-Mimetic Activities Attenuate Radiation-Induced Tissue Damage. Adv Mater. 2024 May;36(19):e2308098. doi: 10.1002/adma.202308098. Epub 2024 Jan 25. PMID: 37777858.
10.Shen L, Qi H, Chen S, Cao F, Xie L, Wu Y, Ma W, Song Z, Yuan H, Zhang T, Li D, Wen X, Chen Q, Li W, Zhang X, Fan W. Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study. Cancer Immunol Immunother. 2020 Sep;69(9):1713-1724. doi: 10.1007/s00262-020-02566-z. Epub 2020 Apr 24. PMID: 32333081; PMCID: PMC7413875.
11.Shen L, Tan H, Nie J, Jiang Y, Nuerhashi G, Qi H, Cao F, Wen C, Chen S, Zhang T, Zheng W, Liu P, Liu Y, Huang T, Li D, Zhang X, Fan W. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy. Cancer Immunol Immunother. 2024 Mar 2;73(4):68. doi: 10.1007/s00262-024-03637-1. PMID: 38430269; PMCID: PMC10908608.
12.Chen S, Wu Y, Qi H, Shen L, Ma W, Cao F, Diao Y, Wang T, Ou S, Fan W. Single-nodule hepatitis B virus-associated hepatocellular carcinoma smaller than 3 cm: two phenotypes defined by cluster analysis and their association with the outcome of ablation as the first-line therapy. Int J Hyperthermia. 2021;38(1):120-129. doi: 10.1080/02656736.2021.1876930. PMID: 33541160.
13.Chen S, Qi H, Tan H, Cao F, Xie L, Huang T, Wu Y, Wen C, Wang Y, Shen L, Fan W. Long-Term Analysis of Recurrence Beyond Milan Criteria Following Ablation of Solitary Early-Stage Hepatocellular Carcinoma ≤3 cm in Potentially Transplantable Patients: A Over 10-Year Survival Study. J Hepatocell Carcinoma. 2025 Feb 3;12:205-218. doi: 10.2147/JHC.S505979. PMID: 39925626; PMCID: PMC11804238.
14.Chen S, Shi M, Shen L, Qi H, Wan W, Cao F, Xie L, Wu Y, Chen G, Mo J, Zhu G, Ye D, Zhang Y, Feng Z, Xu L, Fan W. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. Int J Hyperthermia. 2020;37(1):384-391. doi: 10.1080/02656736.2020.1752400. PMID: 32323585.

Updated by International Office, Sun Yat-sen University Cancer Center

Over the past 20 years, Dr. Zhao performed over 1,200 vascular interventions, ablations, and other interventional procedures for cancer patients care annually, and provided consultations to approximately 4,000 outpatients per year.
As the principal investigator, Dr. Zhao host multiple projects funded by the National Natural Science Foundation and participated in projects under the National Key Research and Development Program of China, along with various international and domestic clinical trials. Dr. Zhao published 130 papers independently and collaboratively, including 70 papers as first or corresponding author. Among these, 53 first/corresponding-author papers were published in international SCI-indexed journals, such as Journal of Clinical Oncology, Gut, Journal of Hepatology, Nature Communications, Radiology, American Journal of Gastroenterology, International Journal of Surgery, Journal for Immunotherapy of Cancer, Liver Cancer, and European Journal of Cancer. Dr. Zhao pioneered the use of the mFOLFOX regimen for hepatic arterial infusion chemotherapy (HAIC) in advanced Hepatocellular Carcinoma (HCC) and delivered an oral presentation on this at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The HAIC-FOLFOX regimen was incorporated into the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer and the China Liver Cancer Staging (CNLC), published by the National Health Commission and the Chinese Society of Clinical Oncology (CSCO). Dr. Zhao led the development of the Chinese Expert Consensus on HAIC for HCC (Hepatology International, 2024). Dr. Zhao participated in the development and revision of several key guidelines and consensus, including the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer led by the National Health Commission and the CSCO, the TACE Clinical Practice Consensus—ISMIO International HCC Expert Collaboration Group (2021), and the Clinical Practice Guidelines for TACE in Chinese HCC.

Awards and Honors
1.First Prize of the Guangdong Science and Technology Progress Award
2.First Prize of the Chinese Medical Science and Technology Progress Award
3.Medical Scientist at Sun Yat-sen University Cancer Center
4.Expert in the Expert Pool of China’s Ministry of Science and Technology
5.Most Influential Young and Middle-aged Doctor in Guangdong Province
6.Best Doctor in Guangzhou

Minimally invasive interventional therapy, systemic therapy, and comprehensive management of liver cancers; image-guided minimally invasive therapies (intervention, ablation) for various solid tumors, along with multi-disciplinary treatment. 

1.Visiting scholar (Research on Tumor Immunology and Translational Medicine), Brigham and Women’s Hospital, Harvard Medical School, April 2011 to September 2013
2.Visiting scholar (Clinical training for liver cancer), Barcelona Clinical Liver Cancer Research Center, Spain, April 2008 to September 2008
3.Doctor’s degree (Oncology), Sun Yat-sen University, China, September 2002 to December 2006
4.Master’s degree (Oncology), Sun Yat-sen University of Medical Sciences, China, September 1997 to July 2000
5.Bachelor’s degree (Clinical medicine), Bangbu Medical University, China, September 1988 to July 1993

1. Zhang YM, Wu XT, Yi JZ, Xu J, Zhang YN, Lyu N, Zhao Ming (Corresponding Author). Matching adjusted indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocelular Carcinoma. Liver Cancer. 2025 Apr 22:1-18. Full text available at: https://maipdf.cn/file/at686b53aa45431/pdf

2. Chen QF, Chen S, Yi JZ, Wang JL, Zhong SX, Jiang XY, Hu Y, Tan GJ, Xu J, Lyu N, Zhao Ming (Corresponding Author). Recommended Ten Years' Follow-Up Strategy for Small Hepatocellular Carcinoma after Radiofrequency Ablation: A Cost-Effectiveness Evaluation. American J Gastroenterology. 2024-10-01;119(10):2052-2060. Full text available at: https://maipdf.cn/file/at67f4ef63c998c/pdf

3. He M, Liu Y, Chen S, Deng H, Feng C, Qiao S, Chen Q, Hu Y, Chen H, Wang X, Jiang X, Xia X, Zhao Ming (Co-corresponding Author), Lyu N. Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma. Nature Communications. 2024 Feb 26;15(1):1754. Full text available at: https://maipdf.cn/file/at67f4efb3c9ab0/pdf

4. Zhao Ming (Corresponding Author), Guo Z, Zou YH, Li X, Yan ZP, Chen MS, Fan WJ, Li HL, Yang JJ, Chen XM, Xu LF, Zhang YW, Zhu KS, Sun JH, Li JP, Jin Y, Yu HP, Duan F, Xiong B, Yin GW, Lin HL, Ma YL, Wang HM, Gu SZ, Si TG, Wang XD, Zhao C, Yu WC, Guo JH, Zhai J, Huang YH, Wang WY, Lin HF, Gu YK, Chen JZ, Wang JP, Zhang YM, Yi JZ, Lyu N. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. Hepatology International.2024 Feb;18(1):4-31. Full text available at: https://maipdf.cn/file/at67f4ec387b241/pdf

5. Chen QF, Lyu N, Wang X, Jiang XY, Hu Y, Chen S, Zhong SX, Huang ZL, Chen M, Zhao Ming (Corresponding Author). Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial. International Journal of Surgery. 2023 Sep 4;109(12):3929–3939. Full text available at: https://maipdf.cn/file/at67f4ec8dbaadd/pdf

6. Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao Ming (Corresponding Author). Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). Journal Clinical Oncology. 2022 Feb 10;40(5):468-480. Full text available at: https://maipdf.cn/file/at67f4efe77e74a/pdf

7. Lyu N, Yi JZ, Zhao Ming (Corresponding Author). Immunotherapy in older patients with hepatocellular carcinoma. European Journal of Cancer. 2022 Feb; 162: 76-98. Full text available at: https://maipdf.cn/file/at67f4f14888350/pdf

8. Deng HJ, Anna Kan, Lyu N, HE M, Huang X, Qiao S, Li SL, LU WH, Xie QK, Chen HM, Lai JF, Chen QF, Jiang XY, Liu S, Zhang ZF, Zhao Ming (Corresponding Author).  Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. Journal of Immunotherapy Cancer 2021;9:e002305. Full text available at: https://maipdf.cn/file/at67f4f1dae0625/pdf

9. Deng HJ,  Kan A, Lyu,Mu LW,  HanY, Liu LZ,  Zhang YY,  Duan YF,  Liao SY, Li SL, Xie QK, Gao TX,  Li YR, Zhang ZF, Zhao Ming (Corresponding Author). Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer; 2020 9:338-357. Full text available at: https://maipdf.cn/file/at67f51176eb761/pdf

10. Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y, Zhang Z, Zheng L, Deng H, Li S, Xie Q, Guo R, Shi M, Xu L, Cai X, Wu P, Zhao Ming (Corresponding Author). Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. Journal of Hepatology. 2018 Jul;69(1):60-69. Full text available at: https://maipdf.cn/file/at67f512ee2200e/pdf

11. Lyu N, Lin YE, Kong YN,Zhang ZF,Liu LZ, Zheng L, Mu LW, Wang JP, Li XS,Pan T, Xie QK, Liu YR, Lin AH, Wu PH, Zhao Ming (Corresponding Author). FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/ leucovorin for advanced hepatocellular carcinoma. Gut. 2017 February Vol 67 No 2 395-397. Full text available at: https://maipdf.cn/file/at67f5153f425ac/pdf

12. Pan T, Xie QK, Lv N, Li XS, Mu LW, Wu PH, Zhao Ming (Corresponding Author).  Percutaneous CT-guided Radiofrequency Ablation for Lymph Node Oligometastases from Hepatocellular Carcinoma: A Propensity Score-matching Analysis. Radiology. 2017 Jan;282(1):259-270. Full text available at: https://maipdf.cn/file/at67f51572dd85d/pdf

Updated by International Office, Sun Yat-sen University Cancer Center

Prof. Gao obtained his Ph.D. at Sun Yat-sen University Cancer Center, P. R. China in 2012. He subsequently completed his postdoctoral research fellowship program at University of Rochester University Medical Center (URMC, USA). He has rich clinical experience in minimally invasive and interventional treatment of hepatocellular carcinoma with portal hypertension (especially TIPS procedure), radiofrequency (microwave) ablation, radioactive seed implantation of solid tumor and biliary stent implantation for malignant obstructive jaundice. As the sponsor and executive chairman, he had hosted 8 consecutive "China Southern TIPS Forum". As the first author and/or corresponding author, Prof. Gao has published over 60 papers in prestigious, international peer-reviewed journals, such as Radiology and European Radiology. He has been supported by the National Natural Science Foundation of China (NSFC) and National Natural Science Foundation of Guangdong, etc.

Prof. Gao has received the First prize of scientific and technological progress of Guangdong Province (2020); Second prize of scientific and technological progress award of China Anti-Cancer Association (2019); "The cutting edge of intervention in China" (2019, CCI); "National Famous doctors in China: Young Pioneer" (2017); Research Fellowship of URMC (University of Rochester Medical Center, USA); "The second prize of national outstanding young interventional physician research award (2015)"; "The first prize of the excellent paper in the 16th Annual Conference of Chinese Interventional Brachyseed Society (CIBS)"; etc.

1.Microwave ablation for solid tumors.

2.Study on the advantage of treatment for hepatic carcinoma with hypersplenism by TACE combined with splenic microwave ablation.

3.Biliary stents placement

6/20/2003 Bachelor of Medical ImagingSun Yat-sen UniversityGuangzhou, China

6/22/2009 Master of Medical ImagingSun Yat-sen University Guangzhou, China

6/26/2012 M.D. of Oncology,Sun Yat-sen University Guangzhou, China

1.Wenliang Zhu#, Zhenkang Qiu#, Huzheng Yan, Zhihui Zhong, Weiwei Jiang, Fujun Zhang,* and Fei Gao* .Retrograde venous coil embolization prior to transarterial chemoembolization in hepatocellular carcinoma with arterio-hepatic venous shunts. Diagn Interv Radiol. 2022 28(6): 616–620.
2.Huzheng Yan#, Zhenkang Qiu#, Zhanwang Xiang, Kai Feng, Mingsheng Huang*, Fei Gao*. TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience. Cancer Imaging. 2022; 22: 13.  
3.Zhenkang Qiu#, Wenliang Zhu#, Huzheng Yan, Guobao Wang, Mengxuan Zuo, Han Qi, Guisong Wang, Weiwei Jiang, Jingbing Xue, Fujun Zhang*, Fei Gao*. Single-Centre Retrospective Study Using Propensity Score Matching Comparing Left Versus Right Internal Jugular Vein Access for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation. Cardiovasc Intervent Radiol. 2022; 45(5): 563–569.
4.Zhenkang Qiu#, Guobao Wang#, Guang Yang, Guisong Wang, Weiwei Jiang, Zixiong Chen, Wenliang Zhu, Huanqing Guo, Fujun Zhang*, Fei Gao*. Transcriptome sequencing-based personalized analysis of hepatocellular carcinoma patients with portal vein tumor thrombus. J Gastrointest Oncol. 2021 Apr; 12(2): 795–805. 
5.Zixiong Chen#, Xiaobo Fu#, Zhenkang Qiu, Maoyuan Mu, Weiwei Jiang, Guisong Wang, Zhihui Zhong, Han Qi*, Fei Gao*. CT-guided 125I Brachytherapy for Hepatocellular Carcinoma in High-risk Locations after Transarterial Chemoembolization Combined with Microwave Ablation: A Propensity Score-matched Study Radiol Oncol. 2023 Mar; 57(1): 127–139. 
6.Zhenkang Qiu#, Guobao Wang#, Huzheng Yan, Han Qi, Mengxuan Zuo, Guisong Wang, Weiwei Jiang, Zixiong Chen, Jingbing Xue, Ligong Lu, Fujun Zhang*, Fei Gao*. TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension. Eur Radiol. 2022; 32(10): 6777–6787. 
7.Huzheng Yan#, Guobao Wang#, Wenliang Zhu, Kai Feng, Wenke Zhu, Xuan Wu, Zhenkang Qiu, Guanyu Chen, Weiwei Jiang, Fujun Zhang*, Fei Gao*. Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites. Transl Oncol. 2020 Dec; 13(12): 100864. 
8.Huzheng Yan#, Ma Luo#, Lifei Wang, Zhenkang Qiu, Zhiqiang Mo, Zhanwang Xiang, Yanling Zhang, Guanyu Chen, Zhihui Zhong, Xiuchen Wang, Fei Gao*, Fujun Zhang*. Clinical efficacy and prognostic factors of CT-guided 125I brachytherapy for the palliative treatment of retroperitoneal metastatic lymph nodes. Cancer Imaging. 2020; 20:25. 
9.Zhenkang Qiu, Gui Song Wang, Fei Gao. Whole-course management of interventional treatment in liver cancer patients with portal hypertension J Interv Med. 2019 May; 2(2): 52–54.Correction in: J Interv Med. 2020 Dec; 3(4): 216.
10.Xiaobo Fu#, Weiwei Jiang#, Maoyuan Mu, Guobao Wang, Han Qi, Zixiong Chen, Mengxuan Zuo*, Fei Gao*. Effect of percutaneous stenting strategy of unresectable malignant hilar biliary obstruction by three‐dimensional reconstruction volumetry. Cancer Med. 2023 Apr; 12(8): 9506–9516.
11.Ye Sheng#, Xiaobo Fu#, Guobao Wang, Maoyuan Mu, Weiwei Jiang, Zixiong Chen, Han Qi*, Fei Gao*. Safety and efficacy of self-expandable metallic stent combined with 125I brachytherapy for the treatment of malignant obstructive jaundice. Cancer Imaging. 2023; 23: 33. 
12.Wang G, Zhang F, Yang B, Xue J, Peng S, Zhong Z, Zhang T, Lu M, Gao F*.   Feasibility and Clinical Value of CT-guided (125)I Brachytherapy for Bilateral Lung Recurrences from Colorectal Carcinoma. Radiology. 2016 Mar;278(3):897-905. 
13.Mo Z#, Zhang T#, Zhang Y, Xiang Z, Yan H, Zhong Z, Gao F*, Zhang  F*.   Feasibility  and clinical value of CT-guided 125I brachytherapy for metastatic soft tissue sarcoma after first-line chemotherapy failure. Eur Radiol. 2018 Mar;28(3):1194-1203. 
14. Yan H#, Xiang Z#, Zhong Z#, Mo Z, Zhang T, Chen G, Zhang F*, Gao F*. CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region. Transl Oncol. 2017 Feb;10(1):90-98. 
15. Yan H#, Mo Z#, Xiang Z, Rong D, Zhang Y, Chen G, Zhong Z, Zhang F*, Gao F*. CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma. J Cancer. 2017 Jul 5;8(11):2104-2113. 
16. Xiang Z#, Mo Z#, Li G#, Gilani S, Zhong Z, Zhang T, Zhang F*, Gao F*. 125I brachytherapy in the palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments. Oncotarget. 2016 Apr 5;7(14):18384-93. 
17. Gao F, Li C, Gu Y, Huang J, Wu P. CT-guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients. Eur J Radiol 2013; 82(2):e70-75. 
18.  Zhang T#, Lu M#, Peng S, Zhang W, Yang G, Liu Z, Singh S, Yang Y, Zhang F*, Gao F*. CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy. J Cancer Res Clin Oncol 2014;140(8):1383-1390. 
19.  Yang G#, Peng S#, Zhang Y, Liu Z, Lu M, Zhang T, Gao F*, Zhang F*. Cell-based assay system to estimate the effect of 125I seeds on cancer cells: effect of osteopontin. Recent Pat Anticancer Drug Discov 2014; 9(2):258-263.
20.  Yang G#, Zhang S#, Gao F#, Liu Z, Lu M, Peng S, Zhang T, Zhang F. 
Osteopontin enhances the expression of HOTAIR in cancer cells via IRF1. Biochim Biophys Acta. 2014; 1839(9):837-848.   
21.  Gao F, Gu YK, Huang JH, Zhao M, Wu PH*. Radiofrequency Ablation of Retroperitoneal Metastatic Lymph Nodes from Hepatocellular Carcinoma, Acad Radiol; 2012; 19(8):1035-1040. 
22.  Gao F, Gu YK, Fan WJ, Zhang L, Huang JH*, Evaluation of transarterial chemoembolization combined with percutaneous ethanol ablation for large hepatocellular carcinoma. World J Gastroenterol; 2011; 17(26):3145-3150.   
23.  Gao F, Gu YK, Shen JX, Li CL, Jiang XY, Huang JH*, Experimental study of  destruction to porcine spleen in vivo by microwave ablation. World J Gastroenterol; 2011; 17(45):5014-5020. 
24. Gao F#, Zhong R#, Li GH, Zhang WD*. Computed tomography and magnetic  resonance imaging findings of inflammatory myofibroblastic tumors of the head  and neck. Acta Radiol, 2014; 55(4):434-440.   
25.  Gao F, He N, Wu PH*. The number of tumor-free axillary lymph nodes removed as a prognostic parameter for node-negative breast cancer. Chin J   2014, 33(11):569-73.
26.  Gao F#, Wang GB#, Xiang ZW#, Yang B, Xue JB, Mo ZQ, Zhong ZH, Zhang T, Zhang FJ *, Fan WJ *. A preoperative mathematic model for computed tomographic guided microwave ablation treatment of hepatic dome tumors. Oncotarget. 2016 May 3;7(18):25949-25959. 
27.  Liu Z#, Gao F#, Yang G, Singh S, Lu M, Zhang T, Zhong  Z, Zhang F, Tang R. Combination of radiofrequency ablation with transarterial  chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol, 2014; 35(8):7407-7413.  
28.  Jingxian Shen, Fei Gao*, Jing Zhao, Yunxian Mo, Peihong Wu. Small hepatocellular carcinoma keeping hypodense during dual phase helical CT scan and correlative pathology, J Biomed Graph Comput, 2013; 3(4):1-7. 
29.  Yongxin Chen, Fei Gao*, Lin Chen, Sheng Peng, Yingjie Huang, Yao Wang. Effectiveness and Safety of CT-Guided 125I Brachytherapy for Lung Metastasis from Hepatocellular Carcinoma. Open Journal of Radiology, 2013; 3:159-164. 
30. Zhanwang Xiang#, Lifei Wang#, Huzheng Yan, Zhihui Zhong, Wangkai Liu, Zhiqiang Mo, Fei Gao*, Fujun Zhang*. 125I seed brachytherapy versus external beam radiation therapy for the palliation of painful bone metastases of lung cancer after one cycle of chemotherapy progression. Oncotarget and Therapy, 2018,11:5183-5193.

Updated by International Office, Sun Yat-sen University Cancer Center

Dr. Peihong Wu, is a professor of Sun Yat-sen University, visiting professor of School of Medicine University of Rochester, USA, and visiting professor of School of Medicine University of Toronto, Canada. He is also the president of the Society of Minimally Invasive Therapy in Oncology, Chinese Anti-Cancer Association; and the director of the Department of Medical Image and Image Guided Therapy, Sun Yat-sen University Cancer Center.He has published 6 books, more than 130 papers in non-SCI journals and 40 peer-reviewed papers on image diagnosis and image-guided therapy in oncology. 

Background
1995-1998 Associate Professor and Vice Director, Department of Medical Image and Image Guided Therapy

1998-present Director and Professor of the Department of Medical Image and Image Guided Therapy, Sun Yat-sen University Cancer Center

1999-2000 Visiting scholar. Interventional Radiology and Imaging Diagnosis MD Anderson Cancer Center 

2001-present Member of Standing Committee of Interventional Therapy on Oncology, Chinese Anti-Cancer Association

2006-present President of the Society of Minimally Invasive Therapy in Oncology, Chinese Anti-Cancer Association2007-present Chairman of the Committee of Minimally Invasive Therapy and Integrated Therapy for Hepatocellular Carcinoma, Chinese Anti-Cancer Association

Honors
2007-present Member of Standing Committee of Chinese Anti-Cancer Association

2010-present Member of Academic Committee Sun Yat-sen University Cancer Center

2010-present Member of Medical Quality Management Committee Sun Yat-sen University Cancer Center

2013-present Award of TOP10DR in interventional radiology in China

2014-present Award of the most outstanding doctors in Sun Yat-sen University

2014-present Member of Board Director of Asian Tumor Ablation Association

2014-present Executive Member of Board Director of Asian Pacific Image-guided Therapy Association.

1. Combination of image-guided minimally invasive therapy with chemotherapy, radiotherapy and surgery.

2. Image-guided minimally invasive therapy combined with bio-immunotherapy.

3. Constructive model and strategy for cancer treatment: at the basis of effective elimination of malignant tumor, maximize the physical function, immunity and life quality of patients.

1982 M.D. Sun Yat-sen University, Guangzhou, China

1982-1985 Resident, Radiology and Clinical Oncology 

1985-1988 Fellow, Radiology and Interventional Radiology 

1988-1995 Attending Doctor, Department of Radiology and Interventional Radiology

Updated by International Office, Sun Yat-sen University Cancer Center

Prof. Huang Jinhua has engaged himself in professional clinical practice for over 20 years, accumulated abundant experience in interventional treatment and minimally invasive surgery for cancer and is proficient in curing cancers with various technologies of minimally invasive surgery and treatment. The primary interventional treatment technologies and the cancers cured include: 1. transarterial chemoembolization of liver cancer; 2. transarterial infusion of cancer; 3. ablation of liver cancer, lung cancer, kidney cancer and other solid tumors with radiofrequency and ablation; 4. comprehensive interventional and minimally invasive treatment for gynecologic refractory tumors; 5. implantation of radioactive particles into tumors; 6. (esophageal stricture, obstruction of biliary tract and venous stenosis) endovascular stent implantation.

1985: Graduated from School of Medicine, Medical College of Nanchang University (undergraduate)

1992: Obtained a master’s degree from Shanghai Jiao Tong University School of Medicine (SJTUSM)

2003 – 2004: Studied in MD Anderson Cancer Center, US

1. Radioablation settings affecting the size of lesions created ex vivo in porcine livers with monopolar perfusion electrodes. Acad Radiol 2010;17(8): 980-984.

2. Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. World J Gastroenterol 2010；16(45): 5766-5772.

3. CT, MRI, and FDG-PET/CT imaging findings of abdominopelvic desmoplastic small round cell tumors: Correlation with histopathologic findings. Eur J Radiol 2010.

4. Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization. World J Gastroenterol 2007，13(48):6593-6597.

Updated by International Office, Sun Yat-sen University Cancer Center

1987: Graduated from undergraduate medical program at Inner Mongolia Medical University.

1997: Obtained a master’s degree in medical imaging and nuclear medicine from Norman Bethune College of Medicine Jilin University.

2006: Obtained a doctoral degree in medical imaging and nuclear medicine from Second Military Medical University

09/2008-12/2008: Acted as a visiting scholar in the Department of Radiology, U.S. Baylor College of Medicine

1．Osteosarcoma:Limb salvaging treatment by ultrasonogrphically guided high intensity focused ultrasound.CancerBiolTher 2009;(12)1102-1108

2．Superficial malignant tumors:Non-invasive treatment with ultrasonographically guided high-Intensity focused ultrasound.CancerBiolTher 2009;8(24)(December15;2009)

3．Short to mid term evaluation of CT-guided I125 brachytherapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma.CancerBiol Ther.2009;8(7):585-590

4. Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 2010 Nov;136(11):1633-40

5. Noninvasive treatment of malignant bone tumors using high-intensity focused ultrasound.Cancer. 2010 Aug 15;116(16):3934-42.

6. Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma. European Journal Cancer. 2010 Sep;46(13):2513-21

7. Microwave ablation treatment of liver cancer with 2,450-MHz cooled-shaft antenna: an experimental and clinical study.Journal of Cancer Research and Clinical Oncology. 2010 Oct;136(10):1507-16

8. An imageable retinoid acid derivative to detect human cancer xenografts and study therapeutic dosing to reduce its toxicity.Contrast Media Mol Imaging. 2010 Nov 30. [Epub ahead of print]

9. Computed tomography and magnetic resonance imaging findings of peripheral primitive neuroectodermal tumors of the head and neck. European Journal of Radiology. 2011 Feb [Epub ahead of print]

10. Ke, S. and F. Zhang, et al. (2012). "Multiple target-specific molecular imaging agents detect liver cancer in a preclinical model." CurrMol Med 12 (8): 944-51.

11.Hu, X. and H. Qiu, et al. (2012). "Recurrent gliomas: comparison of computed tomography (CT)-guided 125I seed implantation therapy and traditional radiochemotherapy." Cancer BiolTher 13 (10): 840-7.

12. Peng, S. and Q. X. Yang, et al. (2014). "Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma." Asian Pac J Cancer Prev 15 (13): 5155-60.

13. Yang, G. and S. Zhang, et al. (2014). "Osteopontin enhances the expression of HOTAIR in cancer cells via IRF1." Biochim Biophys Acta 1839 (9): 837-48.

14. Yang, G. and S. Zhang, et al. (2014). "The inhibitory effects of extracellular ATP on the growth of nasopharyngeal carcinoma cells via P2Y2 receptor and osteopontin." J Exp Clin Cancer Res 33: 53.

15. Zhang, T. and M. Lu, et al. (2014). "CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy." J Cancer Res Clin Oncol 140 (8): 1383-90.

16. Yang, G. and S. Peng, et al. (2014). "Cell-based assay system to estimate the effect of 125I seeds on cancer cells: effect of osteopontin." Recent Pat Anticancer Drug Discov 9 (2): 258-63.

17. Zhang, W. and Y. Zhang, et al. (2014). "Multi-modality imaging to determine the cellular heterogeneity of nasopharyngeal  carcinoma components." Oncotarget 5 (8): 2221-9.

18. Liu, Z. and F. Gao, et al. (2014). "Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis." Tumour Biol.

Updated by International Office, Sun Yat-sen University Cancer Center

Updated by International Office, Sun Yat-sen University Cancer Center

Dr. Gu Yangkui graduated from Sun Yat-sen University of Medical Sciences in 1998 and has worked in the University after obtaining a master’s degree from Sun Yat-sen University in 2002. She completed the training for resident doctors and chief physician at Sun Yat-sen University Cancer Center and was promoted as Associate chief physician in December 2010.

Dr. Gu Yangkui possesses rich clinical experience in minimally invasive surgery of primary liver cancer and colorectal liver metastases and specializes in ablation of liver cancer and stent implantation of various stenosis.

Updated by International Office, Sun Yat-sen University Cancer Center

1. Dynamic prognostication and treatment of cancer using big data. 

2. Enhancing efficacy of immunotherapy through local modulation.

Sun Yat-sen University (SYSU), Major GPA: 3.6/5.0      

Sept. 2007-July, 2015 Clinical Medicine (8-year-program)

1.Shen L#,Chen Q#, Yang C#, Wu Y#, Yuan H, Chen S, Ou S, Jiang Y, Huang T, Ke L,Mo J,Feng Z, Zhou P, Fan W. Role of PRDM1 in Tumor Immunity and Drug Response: APan-Cancer Analysis. FrontPharmacol. 2020 Dec 15;11:593195.

2.Shen L#,Qi H#, Chen S#, Cao F#, Xie L, Wu Y, Ma W, Song Z, Yuan H, Zhang T, Li D, WenX, Chen Q, Li W, Zhang X, Fan W. Cryoablation combined with transarterialinfusion of pembrolizumab (CATAP) for liver metastases of melanoma: anambispective, proof-of-concept cohort study. CancerImmunol Immunother. 2020 Sep;69(9):1713-1724.

3. Shen L,Chen S, Qiu Z, Qi H, Yuan H, Cao F, Xie L, Chen Q, Li W, Fan W. Transarterialchemoembolization combined with apatinib versus transarterial chemoembolizationalone for hepatocellular carcinoma with macroscopic vascular invasion: Apropensity score matching analysis. JCancer Res Ther. 2020 Sep;16(5):1063-1068. doi:10.4103/jcrt.JCRT_801_19.

4.Shen L#,Zeng Q#, Guo P#, Huang J#, Li C, Pan T, Chang B, Wu N, Yang L, Chen Q, Huang T,Li W*, Wu P*. Dynamically prognosticating patients with hepatocellularcarcinoma through survival paths mapping based on time-series data. Nat Commun. 2018 Jun 8;9(1):2230

5.Shen L#,Xi M#, Zhao L, Zhang X, Wang X, Huang Z, Chen Q, Zhang T, Shen J, Liu M, HuangJ. Combination Therapy after TACE for Hepatocellular Carcinoma with MacroscopicVascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. Cancers (Basel). 2018 Dec14;10(12).

6.Shen LJ#,Wang L#, Wang SY, Xie GF, Zeng Q, Shi F, Zhang Y, Wu M, Shu WH, Pan CC, Xia YF,Wu PH*. Imaging-based multi-level subdivision of M1 category in TNM stagingsystem for metastatic nasopharyngeal carcinoma. Radiology.2016 Sep; 280(3):805-14

Updated November 2021 by International Office, Sun Yat-sen University Cancer Center